Arcus Biosciences, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $33M | ↑+26.9% | — | — | — |
| 2025-09-30 | $26M | ↓-45.8% | $-135M | ↓-46.7% | -546.2% |
| 2025-06-30 | $160M | ↑+310.3% | $0 | ↑+100.0% | -5.0% |
| 2025-03-31 | $28M | ↓-80.7% | $-112M | ↓-2700.0% | -435.7% |
| 2024-12-31 | $26M | ↓-76.7% | — | — | — |
| 2024-09-30 | $48M | ↑+50.0% | $-92M | ↓-29.6% | -218.8% |
| 2024-06-30 | $39M | ↑+34.5% | $-93M | ↓-24.0% | -271.8% |
| 2024-03-31 | $145M | ↑+480.0% | $-4M | ↑+95.0% | -11.0% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$33M
↑+26.9% +$7M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
RCUS Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyRCUS Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics